28 related articles for article (PubMed ID: 18722065)
1. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.
Zarogoulidis P; Papanas N; Kioumis I; Chatzaki E; Maltezos E; Zarogoulidis K
Eur J Clin Pharmacol; 2012 May; 68(5):479-503. PubMed ID: 22105373
[TBL] [Abstract][Full Text] [Related]
2. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin.
Nalepa P; Dobryniewska M; Busman T; Notario G
Curr Med Res Opin; 2003; 19(5):411-20. PubMed ID: 13678478
[TBL] [Abstract][Full Text] [Related]
3. [Profile and management of patients consulting for a non severe exacerbation of chronic obstructive pulmonary disease (Pragma survey)].
Léophonte P; Zuck P; Perronne C
Med Mal Infect; 2008 Apr; 38(4):200-7. PubMed ID: 18339501
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval.
Lode H; Eller J; Linnhoff A; Ioanas M;
Eur Respir J; 2004 Dec; 24(6):947-53. PubMed ID: 15572537
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
6. Clinical predictors of bacterial involvement in exacerbations of chronic obstructive pulmonary disease.
van der Valk P; Monninkhof E; van der Palen J; Zielhuis G; van Herwaarden C; Hendrix R
Clin Infect Dis; 2004 Oct; 39(7):980-6. PubMed ID: 15472849
[TBL] [Abstract][Full Text] [Related]
7. [Routine use of extended-release clarithromycin tablets for short-course treatment of acute exacerbations of non-severe COPD].
Léophonte P; Zuck P; Perronne C; Baconnet B
Med Mal Infect; 2008 Sep; 38(9):471-6. PubMed ID: 18722065
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial therapy of acute infectious exacerbation of chronic obstructive pulmonary disease.
Chelidze K; Jgarkava M
Georgian Med News; 2008 Jun; (159):27-30. PubMed ID: 18633147
[TBL] [Abstract][Full Text] [Related]
9. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
Chen AM; Bollmeier SG; Finnegan PM
Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease.
Murphy TF
Curr Opin Pulm Med; 2009 Mar; 15(2):138-42. PubMed ID: 19532029
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations.
Antonescu-Turcu AL; Tomic R
Curr Opin Pulm Med; 2009 Mar; 15(2):120-5. PubMed ID: 19532026
[TBL] [Abstract][Full Text] [Related]
12. Clarithromycin (Biaxin) extended-release tablet: a therapeutic review.
Gotfried MH
Expert Rev Anti Infect Ther; 2003 Jun; 1(1):9-20. PubMed ID: 15482099
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
